The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

K Ohyashiki; Y Aota; D Akahane; A Gotoh; K Miyazawa; Y Kimura; J H Ohyashiki

首页> 外文期刊>Leukemia >The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

【24h】

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

机译：发生骨髓纤维化的骨髓增生异常综合征（MDS）中的JAK2 V617F酪氨酸激酶突变表明一部分MDS患者的骨髓增生性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia》 |2005年第12期|共2页
作者
K Ohyashiki; Y Aota; D Akahane; A Gotoh; K Miyazawa; Y Kimura; J H Ohyashiki;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. [J] . Sokol L, Caceres G, Rocha K, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2010,第6期

机译：遗传性不一致的克隆中出现带有del（5q）的骨髓增生异常综合症（MDS）中的JAK2（V617F）突变。
2. The JAK2 V617F mutation occurs frequently in myelodysplastic|[sol]|myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis [J] . M Kremer, T Horn, T Dechow, Leukemia . 2006,第7期

机译：JAK2 V617F突变在骨髓增生异常[| sol] |骨髓增生性疾病中频繁发生，但在真正的纤维化骨髓增生异常综合征中却不存在
3. Reply to Kremer M et al., The JAK2 V617F mutation occurs frequently in myelodysplastic|[sol]|myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis [J] . K Ohyashiki, J H Ohyashiki Leukemia . 2006,第7期

机译：回复Kremer M等人，JAK2 V617F突变在骨髓增生异常| [sol] |骨髓增生性疾病中频繁发生，但在真正的纤维化骨髓增生异常综合症中却不存在
4. Application of the stochastic Moran Model of population genetics to understanding the timing of a driver mutation in Myelodysplastic Syndrome (MDS) [C] . Tomasz Wojdyla, Taly Glaubach, Seth Corey, IFAC World Congress . 2014

机译：人口遗传学随机莫兰模型在骨髓增生综合征（MDS）中驾驶突变的时间
5. CD16xCD33 bispecific killer cell engager (BiKE) activates natural killer (NK) cells from myelodysplastic syndrome (MDS) patients against primary MDS and myeloidderived suppressor cell (MDSC) CD33-positive targets. [D] . Gleason, Michelle K. 2014

机译：CD16xCD33双特异性杀伤细胞接合剂（BiKE）激活来自骨髓增生异常综合征（MDS）患者的自然杀伤（NK）细胞，以抵抗原发性MDS和髓样抑制细胞（MDSC）CD33阳性靶标。
6. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes [O] . David P. Steensma, Gordon W. Dewald, Terra L. Lasho, -1

机译：在非典型骨髓增生性疾病和骨髓增生异常综合症中JAK2 V617F激活酪氨酸激酶突变均很少发生
7. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients [O] . K Ohyashiki, Y Aota, D Akahane, 2005

机译：Myelodysplastic综合征（MDS）中的JAK2 V617F酪氨酸激酶突变发育骨髓纤维化表明MDS患者的子集中的肌鳞状性质

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

著录项

相似文献

相关主题

期刊订阅